HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effect of chromium supplementation on insulin resistance and ovarian and menstrual cyclicity in women with polycystic ovary syndrome.

Abstract
In women with polycystic ovary syndrome, chromium picolinate (200 microg/d) improves glucose tolerance compared with placebo but does not improve ovulatory frequency or hormonal parameters. This pilot study indicates that future studies in the polycystic ovary syndrome population should examine higher dosages or longer durations of treatment.
AuthorsR Scott Lucidi, Angela C Thyer, Carol A Easton, Alan E C Holden, Robert S Schenken, Robert G Brzyski
JournalFertility and sterility (Fertil Steril) Vol. 84 Issue 6 Pg. 1755-7 (Dec 2005) ISSN: 1556-5653 [Electronic] United States
PMID16359984 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Iron Chelating Agents
  • Picolinic Acids
  • picolinic acid
Topics
  • Adolescent
  • Adult
  • Female
  • Glucose Intolerance (drug therapy)
  • Humans
  • Insulin Resistance
  • Iron Chelating Agents (administration & dosage)
  • Menstrual Cycle (drug effects)
  • Ovary (physiology)
  • Ovulation (drug effects)
  • Picolinic Acids (administration & dosage)
  • Pilot Projects
  • Polycystic Ovary Syndrome (drug therapy, physiopathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: